Nuveen
CGON icon

Nuveen’s CG Oncology CGON Stock Holding History

Nuveen’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
188,420
+60,006
+47% +$3.92M ﹤0.01% 1512
2026
Q1 		$8.69M Sell
128,414
-6,278
-5% -$356K ﹤0.01% 1632
2025
Q4 		$5.59M Sell
134,692
-2,286
-2% -$94.6K ﹤0.01% 1860
2025
Q3 		$5.52M Sell
136,978
-1,804
-1% -$52.4K ﹤0.01% 1859
2025
Q2 		$3.61M Sell
138,782
-27,992
-17% -$675K ﹤0.01% 2039
2025
Q1 		$4.08M Buy
166,774
+55,058
+49% +$1.55M ﹤0.01% 2024
2024
Q4 		$3.2M Sell
111,716
-41,918
-27% -$1.43M ﹤0.01% 2185
2024
Q3 		$5.8M Buy
153,634
+91,768
+148% +$3.22M ﹤0.01% 1916
2024
Q2 		$1.95M Hold
61,866
– – ﹤0.01% 2409
2024
Q1 		$2.72M Buy
+61,866
New +$2.53M ﹤0.01% 2261

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's CGON Position: Q2 2026 in Review

Nuveen increased its CG Oncology (CGON) stake by 47% in Q2 2026, buying an estimated $3.92M and bringing the position to 188,420 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

Nuveen first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Nuveen held 188,420 shares of CG Oncology worth $13.4M as of Q2 2026.
  • Nuveen bought 60,006 CG Oncology shares in Q2 2026, an estimated $3.92M.
  • CG Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1512 holding.
  • Nuveen first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.